<DOC>
	<DOC>NCT02913794</DOC>
	<brief_summary>Fimasartan and Rosuvastatin for hypertension and dyslipidemia control</brief_summary>
	<brief_title>Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Hypertension patients who are taking an antihypertensive agent, including Fimasartan at least 12 weeks or more. Dyslipidemia patients who are taking dyslipidemia drug, including Rosuvastatin at least 12 weeks or more Patients who has blood pressure and lipid levels (Total cholesterol, LDLC, HDLC, nonHDLC, * TG) checks 2 weeks before registration Patients being hospitalized Patients who stop taking Fimasartan or Rosuvastatin within 12 weeks 14 or more consecutive days Patients who have more than 400mg/dl triglyceride(TG) at the registration time</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>